Mersana Therapeutics, Inc. (MRSN)

NASDAQ: MRSN · IEX Real-Time Price · USD
7.25
+0.48 (7.09%)
At close: Dec 2, 2022 4:00 PM
7.21
-0.04 (-0.55%)
After-hours: Dec 2, 2022 4:30 PM EST
7.09%
Market Cap 675.47M
Revenue (ttm) 11.90M
Net Income (ttm) -208.27M
Shares Out 97.64M
EPS (ttm) -2.49
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 847,353
Open 6.7
Previous Close 6.77
Day's Range 6.59 - 7.27
52-Week Range 2.68 - 8.34
Beta 1.72
Analysts Buy
Price Target 18.16 (+150.5%)
Earnings Date Nov 7, 2022

About MRSN

Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet need. It develops XMT-1592, a Dolasynthen ADC targeting NaPi2b-expressing tumor cells, which is in phase I clinical trial for the treatment of ovarian cancer and NSCLC adenocarcinoma. The company also develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen development candidate. It has a strategic research and development partnerships with Merck KGaA and Asana BioSci... [Read more]

Industry Biotechnology
IPO Date Jun 28, 2017
CEO Anna Protopapas
Employees 169
Stock Exchange NASDAQ
Ticker Symbol MRSN
Full Company Profile

Financial Performance

In 2021, MRSN's revenue was $43,000, a decrease of -94.81% compared to the previous year's $828,000. Losses were -$170.06 million, 93.2% more than in 2020.

Financial Statements

Analyst Forecast

According to 13 analysts, the average rating for MRSN stock is "Buy." The 12-month stock price forecast is 18.16, which is an increase of 150.48% from the latest price.

Price Target
$18.16
(150.48% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Mersana Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass., Dec. 02, 2022 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug...

2 days ago - GlobeNewsWire

Mersana Therapeutics, Inc. (MRSN) Reports Q3 Loss, Lags Revenue Estimates

Mersana Therapeutics, Inc. (MRSN) delivered earnings and revenue surprises of -1,933.33% and 85.55%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for ...

3 weeks ago - Zacks Investment Research

Mersana Therapeutics Provides Business Update and Announces Third Quarter 2022 Financial Results

CAMBRIDGE, Mass., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-dru...

4 weeks ago - GlobeNewsWire

Mersana Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass., Nov. 04, 2022 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug...

1 month ago - GlobeNewsWire

Mersana Therapeutics to Host Third Quarter 2022 Conference Call on November 7, 2022

CAMBRIDGE, Mass., Oct. 31, 2022 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-dru...

1 month ago - GlobeNewsWire

Mersana Therapeutics Announces Completion of Enrollment in UPLIFT, a Single-Arm Registrational Trial of Upifitamab Ri...

CAMBRIDGE, Mass., Oct. 06, 2022 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-dru...

1 month ago - GlobeNewsWire

Mersana Therapeutics Announces Launch of Oncology FACETS, a Resource for Healthcare Providers to Advance Knowledge in...

CAMBRIDGE, Mass., Sept. 30, 2022 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company, today announced the launch of Oncology FACETS: an educational ...

2 months ago - GlobeNewsWire

Mersana Therapeutics, Inc. (MRSN) Just Flashed Golden Cross Signal: Do You Buy?

Good things could be on the horizon when a stock experiences a golden cross event. How should investors react?

3 months ago - Zacks Investment Research

Mersana Therapeutics, Inc. (MRSN) Reports Q2 Loss, Tops Revenue Estimates

Mersana Therapeutics, Inc. (MRSN) delivered earnings and revenue surprises of -10% and 34.72%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

3 months ago - Zacks Investment Research

Mersana Therapeutics Provides Business Update and Announces Second Quarter 2022 Financial Results

CAMBRIDGE, Mass., Aug. 08, 2022 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-dru...

3 months ago - GlobeNewsWire

Mersana Therapeutics Announces Option Agreement with GSK for the Co-Development and Commercialization of XMT-2056, an...

CAMBRIDGE, Mass., Aug. 08, 2022 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-dru...

3 months ago - GlobeNewsWire

Mersana Therapeutics to Host Second Quarter 2022 Conference Call on August 8, 2022 and Present at Upcoming Conferences

CAMBRIDGE, Mass., Aug. 03, 2022 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-dru...

4 months ago - GlobeNewsWire

Mersana Therapeutics Chief People Officer Carla Poulson Named One of Savoy Magazine's 2022 Most Influential Black Exe...

CAMBRIDGE, Mass., July 22, 2022 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-dru...

4 months ago - GlobeNewsWire

How Much Upside is Left in Mersana Therapeutics, Inc. (MRSN)? Wall Street Analysts Think 256%

The mean of analysts' price targets for Mersana Therapeutics, Inc. (MRSN) points to a 255.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreem...

4 months ago - Zacks Investment Research

Mersana Therapeutics to Present at Upcoming Investor Conferences

CAMBRIDGE, Mass., May 26, 2022 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug...

6 months ago - GlobeNewsWire

Mersana Therapeutics, Inc. (MRSN) Reports Q1 Loss, Lags Revenue Estimates

Mersana Therapeutics, Inc. (MRSN) delivered earnings and revenue surprises of -90.32% and 89.82%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

6 months ago - Zacks Investment Research

Mersana Therapeutics Provides Business Update and Announces First Quarter 2022 Financial Results

CAMBRIDGE, Mass., May 09, 2022 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug...

6 months ago - GlobeNewsWire

Mersana Therapeutics to Present Preclinical Data on XMT-1660, XMT-2056 and the Immunosynthen Platform at AACR Annual ...

XMT-1660 demonstrates robust activity in preclinical models of breast cancer

8 months ago - GlobeNewsWire

Mersana Therapeutics to Present an Analysis from the Expansion Cohort of the Phase 1 Trial of Upifitamab Rilsodotin a...

CAMBRIDGE, Mass., March 15, 2022 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-dru...

8 months ago - GlobeNewsWire

Mersana Therapeutics to Present at the Cowen 42nd Annual Health Care Conference

CAMBRIDGE, Mass., March 02, 2022 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc., (NASDAQ: MRSN) a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody dr...

9 months ago - GlobeNewsWire

Mersana Therapeutics, Inc. (MRSN) Reports Q4 Loss, Tops Revenue Estimates

Mersana Therapeutics, Inc. (MRSN) delivered earnings and revenue surprises of -1.49% and 10%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

9 months ago - Zacks Investment Research

Mersana Therapeutics Announces Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update

CAMBRIDGE, Mass., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-dru...

9 months ago - GlobeNewsWire

Is a Surprise Coming for Mersana Therapeutics (MRSN) This Earnings Season?

Mersana Therapeutics (MRSN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

9 months ago - Zacks Investment Research

Analysts Estimate Mersana Therapeutics, Inc. (MRSN) to Report a Decline in Earnings: What to Look Out for

Mersana Therapeutics, Inc. (MRSN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

9 months ago - Zacks Investment Research

Janssen Inks Over $1B Pact For Mersana's ADC Technology In Three targets

Mersana Therapeutics Inc MRSN has announced a research collaboration and license agreement with Janssen Biotech Inc, a unit of Johnson & Johnson JNJ, to discover antibody-drug conjugates (ADCs) for thre...

Other symbols: JNJ
10 months ago - Benzinga